Indirect Network Meta-Analysis Ranks Cardiorenal Drugs in Diabetic CKD

This network meta-analysis clarifies relative, though indirect, cardiorenal effects of the three major protective drug classes to guide individualized selection in type 2 diabetes with chronic kidney disease.

GLP-1 receptor agonistsSGLT2 inhibitorsnon-steroidal mineralocorticoid receptor antagonistsfinerenonesemaglutidedapagliflozincanagliflozinempagliflozintype 2 diabeteschronic kidney diseasecardiorenal outcomesnetwork meta-analysisFLOW trial Endocrinology / Diabetes / Obesity

Background Information

SGLT2 inhibitors show promise for renal outcomes in T2D-CKD.

The study evaluates potential cardiovascular and renal benefits and safety profiles of GLP-1 receptor agonists (GLP-1RAs), sodium-glucose co-transporter 2 inhibitors (SGLT2is), and non-steroidal mineralocorticoid receptor antagonists (nsMRAs) in patients with type 2 diabetes and chronic kidney disease (T2D-CKD). SGLT2is showed greater reductions in major kidney outcomes and hospitalization for heart failure compared to nsMRAs and GLP-1RAs, while GLP-1RAs were more favorable for cardiovascular death. Indirect comparisons suggest SGLT2is may offer better renal benefits, but confidence in evidence is low to moderate. Direct comparative trials are needed for conclusive guidance. SGLT2 inhibitors may provide superior renal outcomes in T2D-CKD, yet direct head-to-head trials are needed.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Chen H, Wu X, Yuan M, Ren F, Liu T, Yang L, An X, Zhan Y

Citation: Chen H, Wu X, Yuan M, et al. Efficacy and safety of GLP-1RAs, SGLT2is, and nsMRAs for cardiovascular and renal outcomes in T2DM with CKD: a systematic review and network meta-analysis. Frontiers in endocrinology. 2026;17:1937754. doi:10.3389/fendo.2026.1937754

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →